COMBINATION PREPARATION, PARTICULARLY FOR TREATING PROSTATE CANCER

Composition (A) comprising an inhibitor (I) of 5alpha -reductase; an estrogen receptor beta -agonist (II) and an inhibitor (III) of prostate-specific antigen (PSA), for simultaneous or sequential administration, is new. ACTIVITY : Cytostatic. Results for the effects of individual components on the g...

Full description

Saved in:
Bibliographic Details
Main Authors JARRY, HUBERTUS, POPP, MICHAEL, A, SEIDLOVA-WUTTKE, DANA, WUTTKE, WOLFGANG
Format Patent
LanguageEnglish
French
German
Published 02.04.2008
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Composition (A) comprising an inhibitor (I) of 5alpha -reductase; an estrogen receptor beta -agonist (II) and an inhibitor (III) of prostate-specific antigen (PSA), for simultaneous or sequential administration, is new. ACTIVITY : Cytostatic. Results for the effects of individual components on the growth of prostatic cancer cells are given but no results for the combination of (I)-(III). MECHANISM OF ACTION : Inhibition of 5alpha -reductase and PSA, and agonism of the estrogen receptor, resulting in reduced bioavailability of insulin-like growth factor -1 (which has a proliferation-stimulating effect) and reduced secretion of vascular endothelial growth factor (so inhibiting formation of new blood vessels).
Bibliography:Application Number: EP20060762663